Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Effects of Medication and Parkinson’s Disease Severity on Visually Encoded Memory Guided Reaching
Movement Disorders
P12 - Poster Session 12 (12:00 PM-1:00 PM)
3-007

To examine the effects of medication (on vs. off) and PD severity (mild-to-moderate vs. advanced) on the performance of visually encoded memory guided reaching movements. 

Visual inputs can be used to encode spatial locations and program movements to memorized locations. Studies suggest that the basal ganglia are involved in this visual-motor integration. Patients with Parkinson’s disease (PD), characterized by basal ganglia dysfunction, manifest deficits in visual-motor integration and impairments in memory guided movements. The effects of anti-Parkinsonian medication and PD severity on impairments in visually encoded memory guided movements remain unclear. Examining the effect of medication and PD severity will clarify the role of dopaminergic circuits in visually encoded memory guided reaching and the sustained effectiveness of medication as PD progresses.

Participants with mild-to-moderate (15m, 3f; mean age ± SD: 65.4±5.7 years; off motor UPDRS ± SD, 35.1±8.9) and advanced PD (11m, 3f; 66.2±4 years; 51±13.1) performed a visually encoded memory guided reaching task while on and off medication (12-hour overnight withdrawal), in a completely darkened room, over two separate days. Participants used visual inputs to encode three sequential targets and reached to the memorized targets as accurately as possible. Dependent outcomes included peak velocity and accuracy. All statistical analyses were performed using SAS Proc Mixed.

Medication significantly improved peak velocity (mean difference, 0.35m/s; p<0.01) and accuracy (0.001m; p=0.04) in the mild-to-moderate PD group. Medication had no effect on peak velocity or accuracy in the advanced PD group.

Medication improved performance in a visually encoded memory guided reaching task in the mild-to-moderate PD group but not in the advanced PD group. This supports the critical role of dopaminergic circuits in using visual inputs during memory guided reaching. Our findings also highlight the declining effect of medication as the disease progresses.
Authors/Disclosures

PRESENTER
No disclosure on file
No disclosure on file
No disclosure on file
Gian D. Pal, MD (Rutgers University) Dr. Pal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint. Dr. Pal has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Kyowa Kirin. Dr. Pal has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for CLRM Law. Dr. Pal has stock in Baudax Bio. The institution of Dr. Pal has received research support from National Institutes of Health. The institution of Dr. Pal has received research support from Parkinson's Foundation. Dr. Pal has received personal compensation in the range of $500-$4,999 for serving as a Consultant with RKV Firm.
Leonard Verhagen Metman, MD, PhD (Northwestern University) Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. Dr. Verhagen Metman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitsubishi Tanabe. Dr. Verhagen Metman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Supernus. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AbbVie. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerevel. Dr. Verhagen Metman has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers.
No disclosure on file
Daniel Corcos, PhD (Northwestern University) Daniel Corcos, PhD has nothing to disclose.
No disclosure on file